Tamoxifen

Generic Name
Tamoxifen
Brand Names
Soltamox
Drug Type
Small Molecule
Chemical Formula
C26H29NO
CAS Number
10540-29-1
Unique Ingredient Identifier
094ZI81Y45
Background

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...

Indication

Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions
Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
Associated Therapies
Ovulation induction therapy

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2003-08-07
Last Posted Date
2024-01-02
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
2672
Registration Number
NCT00066703
Locations
🇺🇸

Elkhart General Hospital, Elkhart, Indiana, United States

🇺🇸

Memorial Hospital of South Bend, South Bend, Indiana, United States

🇺🇸

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

and more 225 locations

Premenopausal Endocrine Responsive Chemotherapy Trial

First Posted Date
2003-08-07
Last Posted Date
2016-10-28
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
29
Registration Number
NCT00066807
Locations
🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

🇨🇭

Kantonsspital - St. Gallen, St. Gallen, Switzerland

🇮🇹

Centro di Riferimento Oncologico - Aviano, Aviano, Italy

and more 3 locations

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

First Posted Date
2003-08-07
Last Posted Date
2024-01-02
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
3066
Registration Number
NCT00066690
Locations
🇺🇸

Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Finley Hospital, Dubuque, Iowa, United States

and more 492 locations

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

Phase 3
Completed
Conditions
Interventions
First Posted Date
2003-01-27
Last Posted Date
2015-10-06
Lead Sponsor
NSABP Foundation Inc
Target Recruit Count
19747
Registration Number
NCT00003906
Locations
🇺🇸

Santa Clarita Valley Cancer Center - UCLA, Valencia, California, United States

🇺🇸

Charles A. Sammons Cancer Center, Dallas, Texas, United States

🇺🇸

Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

and more 513 locations

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

Phase 1
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
21
Registration Number
NCT00005822
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio, United States

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

First Posted Date
2003-01-27
Last Posted Date
2016-07-13
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
112
Registration Number
NCT00031720
Locations
🇺🇸

Elkhart General Hospital, Elkhart, Indiana, United States

🇺🇸

Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States

🇺🇸

Kingsbury Center for Cancer Care at Cheshire Medical Center, Keene, New Hampshire, United States

and more 11 locations

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

Phase 1
Completed
Conditions
First Posted Date
2002-12-10
Last Posted Date
2008-03-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT00001436
Locations
🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Phase 3
Completed
Conditions
Interventions
First Posted Date
2002-06-03
Last Posted Date
2014-05-07
Lead Sponsor
Pfizer
Target Recruit Count
4740
Registration Number
NCT00038467
Locations
🇬🇧

Pfizer Investigational Site, Wythenshawe, Manchester, United Kingdom

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Phase 3
Completed
Conditions
First Posted Date
2002-04-24
Last Posted Date
2006-07-19
Lead Sponsor
Eli Lilly and Company
Registration Number
NCT00034125
© Copyright 2024. All Rights Reserved by MedPath